VWM
CRL icon

Vermillion Wealth Management’s Charles River Laboratories CRL Stock Holding History

Vermillion Wealth Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$518 – 1745
2026
Q1 		$518 Buy
+3
New +$556 ﹤0.01% 1002

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vermillion Wealth Management's CRL Position: Q2 2026 in Review

Vermillion Wealth Management sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 3 shares — an estimated $518 sold.

Vermillion Wealth Management first reported a position in CRL in Q1 2026 and held it in 1 quarter. The position peaked at $518 in Q1 2026. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Vermillion Wealth Management reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 3 Charles River Laboratories shares in Q2 2026, an estimated $518.
  • Vermillion Wealth Management first reported a position in Charles River Laboratories in Q1 2026 and held it in 1 quarter.
  • Vermillion Wealth Management's Charles River Laboratories position peaked at $518 in Q1 2026.
  • 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.